Florida’s CS/CS/SB 1768 took effect on July 1, 2025, allowing licensed physicians to perform certain non-FDA-approved stem cell therapies. The law also created strict advertising requirements, including a mandatory disclaimer in every ad. For regenerative medicine practices in Florida and across the country, this law changes how you can market stem cell services. But it is not a green light to make treatment claims. Here is what you need to know.
TLDR: Florida now requires a specific FDA disclaimer in all stem cell advertising, in a font size matching your largest ad text. But complying with this state law does not protect you from federal FDA enforcement. The FDA issued a warning letter to a Florida clinic months after the law took effect. Smart practices comply with both state and federal rules at the same time. Other states are following Florida’s lead, making this a national trend.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing company, not a law firm or compliance consultancy.
If you run a regenerative medicine practice in Florida, you have probably heard about SB 1768. The law passed unanimously in both chambers (37-0 in the Senate, 112-0 in the House) and it creates a state-level framework for certain stem cell therapies.
But here is where most practice owners get tripped up. They hear “the state passed a law allowing stem cell therapy” and think it means they can now promote stem cells freely. That is not what this law does. It creates a narrow authorization with strict guardrails, especially around advertising. And federal FDA rules still apply on top of it.
After 15 years in this industry, I have seen what happens when practices over-market after a regulatory change. They get excited, push the boundaries, and end up with an FDA warning letter or worse. This article is about marketing smart within the new rules, not pushing past them.
[IMAGE: Featured image showing a Florida state outline with legal document and stethoscope overlay, representing the intersection of state law and medical practice marketing | Alt text: “Florida stem cell law SB 1768 marketing requirements for regenerative medicine practices” | Suggested filename: florida-stem-cell-law-marketing-requirements.webp]
What Florida’s SB 1768 actually allows
The law authorizes licensed MDs and DOs in Florida to perform stem cell therapies that the FDA has not approved. But it only applies to three areas: orthopedics, wound care, and pain management. The treatments must fall within the physician’s licensed scope of practice.
The law also sets strict rules about where stem cell products come from. Products must be retrieved, manufactured, and stored in FDA-registered facilities. Those facilities must be accredited by at least one recognized body, such as the American Association of Tissue Banks or the Association for the Advancement of Blood and Biotherapies. Each batch requires a Certificate of Analysis and post-thaw viability testing.
Some stem cell sources are banned under the law. Fetal-derived cells, embryonic tissue from abortions, and adipose-derived mesenchymal stem cells (stem cells from fat tissue) are all prohibited.
What this means for your practice: This is a narrow law. It covers specific therapies, specific providers, and specific product sources. It is not a broad authorization for all regenerative medicine marketing.
The mandatory advertising disclaimer you must include
This is the most important section for anyone marketing stem cell services in Florida. The law requires a specific disclaimer in every form of advertising. Digital ads, print ads, in-office signs, websites, social media posts: all of them.
Here is the exact language required by the statute:
“THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This health care practitioner performs one or more stem cell therapies that the United States Food and Drug Administration has not yet approved. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.”
The disclaimer must appear in a font size no smaller than the largest font size used in the ad. If your headline is in 24-point font, the disclaimer must be in 24-point font too. This is not a fine-print requirement. Florida wants patients to see this notice clearly.
The same notice must also be provided in writing to each patient at your clinic and displayed in your office.
One important detail: legal analysts have noted that the word “yet” in the phrase “has not yet been approved” could be misleading. As the FIDJ Law analysis points out, this language implies that future FDA approval is expected, which is not guaranteed. From a marketing compliance perspective, be aware that this phrasing comes from the statute itself, not from your practice. But it does not change your obligation to avoid making treatment claims that violate federal law.
What this means for your practice: If you advertise stem cell services in Florida, this disclaimer is not optional. It must be in every ad, in a font size matching your largest text. Missing it can lead to disciplinary action from the Florida Department of Health.
[IMAGE: Example mockup of a compliant stem cell advertisement with the required Florida disclaimer displayed at proper font size | Alt text: “Example of compliant Florida stem cell therapy advertisement with mandatory disclaimer” | Suggested filename: florida-stem-cell-ad-disclaimer-example.webp]
Why state compliance does not protect you from the FDA
This is the part most practice owners miss. Complying with Florida’s law does not shield you from federal enforcement. The FDA’s position has not changed.
According to a legal analysis from Holland & Knight, Florida’s law is in direct conflict with the Federal Food, Drug, and Cosmetic Act (FDCA). Federal law requires products to have FDA approval before being marketed for treating, curing, or mitigating disease. Under the Supremacy Clause of the Constitution, federal law generally overrides conflicting state law.
The evidence is clear. In September 2025, the FDA issued a warning letter to New Life Medical Services in Lutz, Florida, for marketing unapproved stem cell and exosome products. This was months after SB 1768 took effect. The state law did not stop the warning letter.
In October 2025, the U.S. Supreme Court declined to review the FDA’s enforcement case against US Stem Cell Clinic, a Florida-based clinic. This affirmed the federal court ruling that stem cell products from adipose tissue are drugs requiring FDA approval. The FDA’s consumer alert on regenerative medicine products remains in effect, warning that most stem cell therapies marketed to consumers are unapproved.
| Rule Set | What It Says About Stem Cell Marketing |
|---|---|
| Florida SB 1768 | Allows marketing with mandatory disclaimer |
| Federal FDA | Unapproved products cannot be marketed as treating disease |
| FTC | All health advertising must be truthful and substantiated |
What this means for your practice: You must comply with both. Include the Florida disclaimer AND avoid making disease-treatment claims. A practice can be fully compliant with SB 1768 and still receive an FDA warning letter if the ad copy promises to treat, cure, or heal a specific condition.
This overview is educational and reflects publicly available regulatory information as of March 2026. Regulations change frequently, and enforcement varies by jurisdiction. Always consult qualified legal counsel before making compliance decisions for your practice or business.
What compliant stem cell marketing looks like (and what does not)
The safest approach is what we call “double compliance.” Meet Florida’s requirements and stay within federal rules at the same time. Here is a practical guide.
| Non-Compliant (Risky) | Compliant (Safer) |
|---|---|
| “Our stem cell therapy cures knee arthritis” | “Our practice offers consultation for patients interested in regenerative approaches to joint health” |
| “FDA-approved stem cell treatment” | Includes the mandatory Florida disclaimer stating the therapy is NOT FDA-approved |
| “Stem cells eliminate your pain” | “Learn about the options available at our practice for patients with orthopedic concerns” |
| No disclaimer in Facebook ad | Full disclaimer in matching font size in every ad format |
| Fine-print disclaimer at the bottom | Disclaimer in font size matching the largest text in the ad |
The left column violates federal law, state law, or both. The right column meets Florida’s disclaimer requirement while avoiding the disease-treatment claims that trigger FDA enforcement.
Your paid advertising and content creation should follow this double-compliance framework for every piece of marketing material.
How this looks in practice
Consider a regenerative medicine clinic in Central Florida that launches a new stem cell marketing campaign after SB 1768 takes effect. They include the state-mandated disclaimer in their ads. But their Facebook ad headline reads “Stem Cell Therapy Eliminates Arthritis Pain” and their landing page promises that “stem cells treat and heal damaged joints.”
The Challenge: The clinic believed that because they included Florida’s required disclaimer, they were covered. They were not.
The Compliance Problem: The ad copy makes disease-treatment claims for an unapproved product. This violates the FDCA regardless of state law. It also likely violates Meta’s health advertising policies and FTC advertising standards.
The Risk: An FDA warning letter, possible FTC enforcement, Meta ad account suspension, and potential disciplinary action from the Florida Department of Health for misrepresenting the treatment.
The Fix: The clinic rewrites the headline to “Explore Regenerative Options for Joint Health” and replaces the landing page claims with educational content about the consultation process, including the full mandatory disclaimer. They shift from treatment promises to education and consultation framing.
Note: This scenario is illustrative and does not reference any specific Regen Portal client.
The national trend: other states following Florida
Florida is not alone. A growing number of states are passing laws that create state-level frameworks for non-FDA-approved stem cell therapies.
| State | Law | Status | Key Difference |
|---|---|---|---|
| Florida | SB 1768 | Effective July 2025 | Allogeneic (donor) stem cells for orthopedics, wound care, pain |
| Wyoming | SF 48 | Advancing (Feb 2026) | Autologous (patient’s own) cells with IRB oversight |
| Utah | Stem cell law | Enacted | Placental cell products |
| Nevada | Biologics law | Enacted | Broad scope including gene therapies |
| Texas | SB 1827 | Introduced 2025 | Investigational stem cell treatment |
This trend matters for every regenerative medicine practice, not just those in Florida. As more states pass these laws, the marketing landscape gets more complex. Each state may have different disclaimer requirements, different authorized therapies, and different enforcement mechanisms.
What this means for your practice: If you operate in multiple states or market nationally, your compliance obligations just got more complicated. You need to track which states have these laws, what each one requires, and how they interact with federal rules. A marketing partner who understands this landscape can help you stay ahead of the changes.
For more on building a marketing strategy that adapts to regulatory changes, explore Regen Portal’s full services.
For regular updates on compliance and marketing in regenerative medicine, subscribe to Oscar’s YouTube channel: https://www.youtube.com/@oatellez.
Frequently asked questions
What does Florida’s stem cell law (SB 1768) actually allow?
It allows licensed MDs and DOs in Florida to perform non-FDA-approved stem cell therapies for orthopedics, wound care, and pain management. Products must come from FDA-registered, accredited facilities. Fetal-derived cells, embryonic tissue, and adipose-derived stem cells are banned.
What is the exact disclaimer language I need in all my advertising?
The statute requires this exact notice: “THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW. This health care practitioner performs one or more stem cell therapies that the United States Food and Drug Administration has not yet approved. You are encouraged to consult with your primary care provider before undergoing any stem cell therapy.”
How big does the disclaimer need to be in my ads?
The disclaimer must be in a font size no smaller than the largest font size used in the advertisement. It is not a fine-print requirement.
Does this law mean I can now make treatment claims in my marketing?
No. The state law creates a framework for offering certain therapies with a required disclaimer. It does not override federal FDA rules, which prohibit marketing unapproved products as treating, curing, or mitigating disease.
Can I still get an FDA warning letter even if I comply with Florida’s law?
Yes. The FDA issued a warning letter to a Florida clinic in September 2025, after SB 1768 took effect. Federal law operates independently of state law, and the Supremacy Clause generally gives federal rules priority.
Do other states have similar laws?
Yes. Utah, Nevada, Wyoming, and Texas have enacted or introduced similar legislation. Each state’s law has different scope and requirements.
What happens if I do not include the disclaimer?
Failure to include the mandatory disclaimer can result in disciplinary action from the Florida Department of Health or licensing board. Penalties can include fines, license restrictions, or worse.
Key takeaways
- SB 1768 is narrow. It covers specific therapies, specific providers, and specific product sources. It is not a broad marketing authorization.
- The disclaimer is mandatory. Every ad must include the full statutory notice in a font size matching your largest ad text.
- State compliance does not equal federal compliance. The FDA continues to enforce against Florida clinics regardless of SB 1768.
- Double compliance is the safest approach. Meet Florida’s requirements AND avoid disease-treatment claims under federal law.
- The “yet” language is a concern. The disclaimer implies future FDA approval, which is not guaranteed. Be aware of this when framing your marketing.
- This is a national trend. Wyoming, Utah, Nevada, and Texas are following Florida’s lead. Track these changes if you market in multiple states.
Questions about compliant marketing for stem cell services?
Navigating the intersection of state and federal rules is one of the hardest parts of marketing a regenerative medicine practice. Regen Portal was built for this challenge. With over 15 years of experience in the regenerative medicine industry, we understand the rules, the risks, and the strategies that keep practices visible while staying compliant.
If you need help building a search engine optimization or advertising strategy that works within these new regulations, let’s talk.
Email: hello@regenportal.com Website: regenportal.com YouTube: Subscribe for weekly insights
About Regen Portal
Regen Portal is a marketing company serving the regenerative medicine industry. We provide SEO, content creation, social media management, paid advertising, website development, and branding services for clinics, manufacturers, distributors, and independent providers. Some strategies discussed in our educational content align with services we offer. For more information, visit regenportal.com or contact us.
Oscar Tellez is the founder of Regen Portal, a marketing company built for the regenerative medicine industry. With over 15 years of experience spanning clinical operations, product distribution, and digital marketing, Oscar has helped hundreds of practices, manufacturers, and distributors grow through compliant, high-performance marketing strategies. He holds a B.S. in Exercise Physiology and Health Promotion from Florida Atlantic University.